Trial reportBMC medicine2019
Safety, activity, and molecular heterogeneity following neoadjuvant non-pegylated liposomal doxorubicin, paclitaxel, trastuzumab, and pertuzumab in HER2-positive breast cancer (Opti-HER HEART): an open-label, single-group, multicenter, phase 2 trial.
Open access · goldAbstract readClinical Trial, Phase IIMulticenter Study
In one paragraph
Trial report in BMC medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 3 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed, 3 pooled it
2.2field-weighted citation impact, top 11% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 3 syntheses or guidelines pooled it, 35 citations in OpenAlex.
- Comparing Biomarkers for Predicting Pathological Responses to Neoadjuvant Therapy in HER2-Positive Breast Cancer: A Systematic Review and Meta-Analysis.Frontiers in oncology · 2021Pooled it
- Meta-Analysis of HER2-Enriched Subtype Predicting the Pathological Complete Response Within HER2-Positive Breast Cancer in Patients Who Received Neoadjuvant Treatment.Frontiers in oncology · 2021Pooled it
- HER2-enriched subtype and pathological complete response in HER2-positive breast cancer: A systematic review and meta-analysis.Cancer treatment reviews · 2020Pooled it
- A Phase II Study of Neoadjuvant PLD/Cyclophosphamide and Sequential nab-Paclitaxel Plus Dual HER2 Blockade in HER2-Positive Breast Cancer.The oncologist · 2024Trial
- Phenotypic changes of HER2-positive breast cancer during and after dual HER2 blockade.Nature communications · 2020Trial
- Impact of quality control indicator system management program on neoadjuvant and adjuvant therapies for breast cancer: a comparative analysis.Frontiers in oncology · 2026Article
- Dual HER2 inhibition: mechanisms of synergy, patient selection, and resistance.Nature reviews. Clinical oncology · 2024Review
- Sequential neoadjuvant chemotherapy using pegylated liposomal doxorubicin and cyclophosphamide followed by taxanes with complete trastuzumab and pertuzumab treatment for HER2-positive breast cancer: A phase II single-arm study.Chinese journal of cancer research = Chung-kuo yen cheng yen chiu · 2024Article
- Multi-task learning for predicting synergistic drug combinations based on auto-encoding multi-relational graphs.iScience · 2023Article
- Neoadjuvant pertuzumab in non-metastatic HER2-positive breast tumors: Multicentric study in Peru (NeoHer).Molecular and clinical oncology · 2022Article
- Pegylated Liposomal Doxorubicin, Docetaxel, and Trastuzumab as Neoadjuvant Treatment for HER2-Positive Breast Cancer Patients: A Phase II and Biomarker Study.Frontiers in oncology · 2022Article
- Neoadjuvant eribulin in HER2-negative early-stage breast cancer (SOLTI-1007-NeoEribulin): a multicenter, two-cohort, non-randomized phase II trial.NPJ breast cancer · 2021Article
- Review
- Independent Validation of the PAM50-Based Chemo-Endocrine Score (CES) in Hormone Receptor-Positive HER2-Positive Breast Cancer Treated with Neoadjuvant Anti-HER2-Based Therapy.Clinical cancer research : an official journal of the American Association for Cancer Research · 2021Article
- Case Report: Postoperative Recurrence of Adrenal Epithelioid Angiosarcoma Achieved Complete Response by Combination Chemotherapy With Liposomal Doxorubicin and Paclitaxel.Frontiers in oncology · 2021Article
- The Peony trial: adding evidence to pertuzumab use in non-metastatic breast cancer.Gland surgery · 2020Article
- Combination of pegylated liposomal doxorubicin and docetaxel as neoadjuvant therapy for breast cancer with axillary lymph node metastasis.The Journal of international medical research · 2020Article
- HER2-Enriched Subtype and ERBB2 Expression in HER2-Positive Breast Cancer Treated with Dual HER2 Blockade.Journal of the National Cancer Institute · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors at 16 institutions in 2 countries.
Joaquín GaviláFundación Instituto Valenciano de Oncología, Valencia, Spain.
Mafalda OliveiraVall d' Hebron University Hospital/Vall d'Hebron Institute of Oncology, Barcelona, Spain.
Tomás PascualAugust Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain.
Jose Perez-GarciaVall d' Hebron University Hospital/Vall d'Hebron Institute of Oncology, Barcelona, Spain.
Xavier GonzàlezSOLTI Breast Cancer Research Group, Barcelona, Spain.
Jordi CanesSOLTI Breast Cancer Research Group, Barcelona, Spain.
Laia ParéAugust Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain.
Isabel CalvoCentro Integral Oncológico Clara Campal, Madrid, Spain.
Eva CiruelosHospital 12 de Octubre, Madrid, Spain.
Montserrat MuñozAugust Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain.
Juan A VirizuelaHospital Universitario Virgen Macarena, Sevilla, Spain.
Isabel RuizHospital Universitario Sant Joan De Reus, Reus, Spain.
Raquel AndrésHospital Clínico Universitario Lozano Blesa, Zaragoza, Spain.
Antonia PerellóHospital Universitario Son Espases, Palma, Spain.
Jerónimo MartínezHospital Universitario Virgen Arrixaca, Murcia, Spain.
Serafín MoralesHospital Universitari Arnau Vilanova, Lleida, Spain.
Mercedes Marín-AguileraAugust Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain.
Débora MartínezAugust Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain.
Juan C QueroHospital Sagrado Corazón, Barcelona, Spain.
Antonio Llombart-CussacHospital Arnau de Vilanova, Valencia, Spain.
Aleix PratAugust Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain. alprat@clinic.cat.ORCID 0000-0003-2377-540X
Consorci Institut D'Investigacions Biomediques August Pi I Sunyer · ESHospital Clínic de Barcelona · ESInstituto Oncológico Dr. Rosell · ESBreast Cancer Research Foundation · USCentro Oncológico de Galicia · ESFundación Instituto Valenciano de Oncología · ESHospital Arnau de Vilanova · ESHospital Clínico Universitario Lozano Blesa · ESHospital Quirónsalud Sagrado Corazón · ESHospital Universitari Arnau de Vilanova · ESHospital Universitario Son Espases · ESHospital Universitario Virgen de la Arrixaca · ESHospital Universitario Virgen Macarena · ESHospital Universitari Sant Joan de Reus · ESResearch Institute Hospital 12 de Octubre · ESVall d'Hebron Hospital Universitari · ES
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
AdultAgedAntibodies, Monoclonal, HumanizedAntineoplastic Combined Chemotherapy ProtocolsBreast NeoplasmsCardiotoxicityChemotherapy, AdjuvantDoxorubicinErb-b2 Receptor Tyrosine KinasesFemaleHumansMiddle AgedNeoadjuvant TherapyPaclitaxelPolyethylene GlycolsTrastuzumabAntibodies, Monoclonal, HumanizedDoxorubicinErb-b2 Receptor Tyrosine Kinasesliposomal doxorubicinPaclitaxelpertuzumabPolyethylene GlycolsTrastuzumabBreast cancercardiac safetyHER2HER2-enrichedintrinsic subtypesneoadjuvantPAM50
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.